Which has higher earnings and valuation, NUVB or PCVX?

Nuvation Bio has higher revenue and earnings than Vaxcyte. Nuvation Bio is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $62.90M 38.63 -$204.63M -$0.44 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is NUVB or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Vaxcyte's return on equity of -37.56% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -88.18% -46.59% -22.01% Vaxcyte N/A -37.56% -33.62%

Does the media refer more to NUVB or PCVX?

In the previous week, Nuvation Bio had 10 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Nuvation Bio and 4 mentions for Vaxcyte. Nuvation Bio's average media sentiment score of 0.46 beat Vaxcyte's score of 0.42 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NUVB or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -88.18% -46.59% -22.01% Immunovant N/A -69.59% -62.49%

Does the media prefer NUVB or IMVT?

In the previous week, Nuvation Bio had 6 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Nuvation Bio and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.81 beat Nuvation Bio's score of 0.46 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVB or APGE?

In the previous week, Nuvation Bio had 9 more articles in the media than Apogee Therapeutics. MarketBeat recorded 14 mentions for Nuvation Bio and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.91 beat Nuvation Bio's score of 0.46 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apogee Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NUVB or ALKS?

Alkermes has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $62.90M 38.63 -$204.63M -$0.44 N/A Alkermes $1.48B 5.49 $241.66M $0.38 127.18

Is NUVB or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Nuvation Bio's net margin of -88.18%. Alkermes' return on equity of 4.15% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -88.18% -46.59% -22.01% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to NUVB or ALKS?

In the previous week, Nuvation Bio had 10 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for Nuvation Bio and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.02 beat Nuvation Bio's score of 0.46 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVB or IBRX?

In the previous week, Nuvation Bio had 12 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for Nuvation Bio and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.26 beat Nuvation Bio's score of 0.46 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nuvation Bio (NUVB) Competitors

$6.92 +0.09 (+1.32%)

As of 08/21/2026 03:58 PM Eastern

Compare

NUVB vs. PCVX, IMVT, APGE, ALKS, and IBRX

Should you buy Nuvation Bio stock or one of its competitors? Nuvation Bio's main competitors and comparable companies include Vaxcyte (PCVX), Immunovant (IMVT), Apogee Therapeutics (APGE), Alkermes (ALKS), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvation Bio compare to Vaxcyte?

Nuvation Bio (NYSE:NUVB) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Nuvation Bio currently has a consensus target price of $13.00, indicating a potential upside of 87.86%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 37.34%. Given Nuvation Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvation Bio is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vaxcyte has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Vaxcyte's return on equity of -37.56% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Vaxcyte	N/A	-37.56%	-33.62%

In the previous week, Nuvation Bio had 10 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Nuvation Bio and 4 mentions for Vaxcyte. Nuvation Bio's average media sentiment score of 0.46 beat Vaxcyte's score of 0.42 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nuvation Bio has higher revenue and earnings than Vaxcyte. Nuvation Bio is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	38.63	-$204.63M	-$0.44	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Nuvation Bio has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Summary

Nuvation Bio beats Vaxcyte on 11 of the 15 factors compared between the two stocks.

How does Nuvation Bio compare to Immunovant?

Nuvation Bio (NYSE:NUVB) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunovant has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Immunovant	N/A	-69.59%	-62.49%

In the previous week, Nuvation Bio had 6 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Nuvation Bio and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.81 beat Nuvation Bio's score of 0.46 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Nuvation Bio currently has a consensus target price of $13.00, suggesting a potential upside of 87.86%. Immunovant has a consensus target price of $44.00, suggesting a potential downside of 0.83%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nuvation Bio has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	38.63	-$204.63M	-$0.44	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Summary

Nuvation Bio beats Immunovant on 13 of the 15 factors compared between the two stocks.

How does Nuvation Bio compare to Apogee Therapeutics?

Nuvation Bio (NYSE:NUVB) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Nuvation Bio has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Nuvation Bio has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	38.63	-$204.63M	-$0.44	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

In the previous week, Nuvation Bio had 9 more articles in the media than Apogee Therapeutics. MarketBeat recorded 14 mentions for Nuvation Bio and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.91 beat Nuvation Bio's score of 0.46 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Apogee Therapeutics' return on equity of -29.88% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Apogee Therapeutics	N/A	-29.88%	-28.08%

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nuvation Bio currently has a consensus price target of $13.00, indicating a potential upside of 87.86%. Apogee Therapeutics has a consensus price target of $124.43, indicating a potential downside of 7.66%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Nuvation Bio is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.20

Summary

Nuvation Bio beats Apogee Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Alkermes?

Nuvation Bio (NYSE:NUVB) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvation Bio presently has a consensus target price of $13.00, suggesting a potential upside of 87.86%. Alkermes has a consensus target price of $54.56, suggesting a potential upside of 12.90%. Given Nuvation Bio's higher probable upside, equities research analysts clearly believe Nuvation Bio is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Alkermes has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	38.63	-$204.63M	-$0.44	N/A
Alkermes	$1.48B	5.49	$241.66M	$0.38	127.18

In the previous week, Nuvation Bio had 10 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for Nuvation Bio and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.02 beat Nuvation Bio's score of 0.46 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has a net margin of 3.96% compared to Nuvation Bio's net margin of -88.18%. Alkermes' return on equity of 4.15% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Alkermes	3.96%	4.15%	2.19%

Summary

Alkermes beats Nuvation Bio on 12 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to ImmunityBio?

Nuvation Bio (NYSE:NUVB) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market.

Nuvation Bio currently has a consensus price target of $13.00, indicating a potential upside of 87.86%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 82.28%. Given Nuvation Bio's higher probable upside, research analysts clearly believe Nuvation Bio is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Nuvation Bio had 12 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for Nuvation Bio and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.26 beat Nuvation Bio's score of 0.46 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a net margin of -88.18% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
ImmunityBio	-598.55%	N/A	-51.65%

Nuvation Bio has higher earnings, but lower revenue than ImmunityBio. Nuvation Bio is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	38.63	-$204.63M	-$0.44	N/A
ImmunityBio	$113.29M	72.88	-$351.40M	-$0.97	N/A

Summary

Nuvation Bio beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVB vs. The Competition

Export

Metric	Nuvation Bio	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.43B	$4.01B	$7.37B	$24.30B
Dividend Yield	N/A	3.64%	2.53%	3.70%
P/E Ratio	-15.73	11.62	272.60	30.31
Price / Sales	38.63	1,334.62	624.33	19.95
Price / Cash	N/A	105.14	78.62	32.49
Price / Book	9.61	16.80	13.05	6.77
Net Income	-$204.63M	-$12.50M	$3.47B	$1.07B
7 Day Performance	10.99%	3.29%	2.09%	-0.65%
1 Month Performance	6.49%	8.23%	6.64%	3.38%
1 Year Performance	139.28%	55.05%	25.02%	14.90%

Nuvation Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVB Nuvation Bio	3.7227 of 5 stars	$6.92 +1.3%	$13.00 +87.9%	+139.3%	$2.43B	$62.90M	N/A	60	News Coverage Analyst Forecast Insider Trade Gap Up
PCVX Vaxcyte	1.9729 of 5 stars	$60.22 +3.7%	$86.00 +42.8%	+93.9%	$8.64B	N/A	N/A	160
IMVT Immunovant	1.4153 of 5 stars	$43.71 +4.5%	$44.00 +0.7%	+191.1%	$8.64B	N/A	N/A	120
APGE Apogee Therapeutics	1.3054 of 5 stars	$134.59 +0.0%	$124.43 -7.5%	+252.1%	$8.37B	N/A	N/A	91
ALKS Alkermes	3.1837 of 5 stars	$49.85 +1.6%	$54.56 +9.5%	+62.5%	$8.23B	$1.48B	131.19	2,050	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NUVB) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvation Bio (NUVB) Competitors

NUVB vs. PCVX, IMVT, APGE, ALKS, and IBRX

How does Nuvation Bio compare to Vaxcyte?

Summary

How does Nuvation Bio compare to Immunovant?

Summary

How does Nuvation Bio compare to Apogee Therapeutics?

Summary

How does Nuvation Bio compare to Alkermes?

Summary

How does Nuvation Bio compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvation Bio (NUVB) Competitors

NUVB vs. PCVX, IMVT, APGE, ALKS, and IBRX

How does Nuvation Bio compare to Vaxcyte?

Do analysts rate NUVB or PCVX?

Is NUVB or PCVX more profitable?

Does the media refer more to NUVB or PCVX?

Do institutionals & insiders have more ownership in NUVB or PCVX?

Which has higher earnings and valuation, NUVB or PCVX?

Which has more risk and volatility, NUVB or PCVX?

Summary

How does Nuvation Bio compare to Immunovant?

Do insiders & institutionals hold more shares of NUVB or IMVT?

Is NUVB or IMVT more profitable?

Does the media prefer NUVB or IMVT?

Which has more risk and volatility, NUVB or IMVT?

Do analysts recommend NUVB or IMVT?

Which has higher earnings & valuation, NUVB or IMVT?

Summary

How does Nuvation Bio compare to Apogee Therapeutics?

Which has more volatility & risk, NUVB or APGE?

Which has higher valuation and earnings, NUVB or APGE?

Does the media refer more to NUVB or APGE?

Is NUVB or APGE more profitable?

Do institutionals & insiders believe in NUVB or APGE?

Do analysts recommend NUVB or APGE?

Summary

How does Nuvation Bio compare to Alkermes?

Do insiders and institutionals believe in NUVB or ALKS?

Do analysts rate NUVB or ALKS?

Which has more risk and volatility, NUVB or ALKS?

Which has stronger valuation and earnings, NUVB or ALKS?

Does the media refer more to NUVB or ALKS?

Is NUVB or ALKS more profitable?

Summary

How does Nuvation Bio compare to ImmunityBio?

Which has more risk & volatility, NUVB or IBRX?

Do analysts rate NUVB or IBRX?

Do institutionals and insiders have more ownership in NUVB or IBRX?

Does the media refer more to NUVB or IBRX?

Is NUVB or IBRX more profitable?

Which has better valuation and earnings, NUVB or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools